Biomarkers are important for guiding the clinical and therapeutic management of all phases
of rheumatoid arthritis because they can help to predict disease development in subjects at …

No new therapy has been approved for systemic lupus erythematosus (SLE) in decades.
Interest in SLE by pharmaceutical and biotechnology companies has increased, leading to …

Systemic lupus erythematosus (SLE) is a complex autoimmune disorder of unknown
etiology. Multifactorial interaction among various susceptible factors such as environmental …

Systemic lupus erythematosus (SLE) is a chronic autoimmune disease with a wide range of
clinical manifestations and a relapsing-remitting course. New data regarding pathogenic …

Introduction Auto-immune diseases are complex and heterogeneous. Various types of
biomarkers can be used to support precision medicine approaches to autoimmune …

There is no serologic test that reliably measures disease activity in systemic lupus
erythematosus (SLE). The 'gold standard'is the anti-dsDNA antibody test, which has been …

Lupus nephritis (LN) occurs in up to 60% of SLE patients, and is a leading cause of disability
and death. Current treatment of LN consists of a combination of high dose corticosteroids …

The current treatment approach for systemic lupus erythematosus (SLE), as outlined in the
recommendations by international medical associations including EULAR and the ACR, is …

Purpose The author9s goal is to review recent phase III clinical trials in patients with
systemic lupus erythematosus (SLE), with emphasis on outcomes and on mechanisms by …

Systemic lupus erythematosus (SLE) is a complex autoimmune multisystemic disease of
great clinical heterogeneity and significant potential morbidity and mortality. Although the …